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Untargeted metabolomics by high 
resolution mass spectrometry 
coupled to normal and reversed 
phase liquid chromatography 
as a tool to study the in vitro 
biotransformation of new 
psychoactive substances
sascha K. Manier  1, Andreas Keller  2, Jan schäper3 & Markus R. Meyer1
In 2016, several synthetic cathinones were seized by the State Bureau of Criminal Investigation 
Bavaria in Germany. Due to their previous appearances in other countries their metabolism was 
already investigated in human urine as well as different in vitro models. these investigations were 
conducted using ordinary metabolism studies for drugs of abuse by using general knowledge about 
drug metabolism and visual comparison of mass spectra. the present study aimed to use untargeted 
metabolomics to support and improve those methods that highly depend on the investigators 
experience. Incubations were conducted using pooled human liver microsomes (pHLM) and the two 
cathinones 1-phenyl-2-(1-pyrrolidinyl)-1-butanone and 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone. 
Samples were analyzed by LC-HRMS/MS using a metabolomics workflow consisting of a reversed 
phase or normal phase separation followed by electrospray ionization and full scan in positive or 
negative mode. LC-MS data was afterwards statistically evaluated using principal component analysis, 
t-distributed stochastic neighborhood embedding, and hierarchical clustering. Significant features 
were then identified using MS/MS. The workflow revealed 24 significant features after 1-phenyl-2-(1-
pyrrolidinyl)-1-butanone and 39 after 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone incubation, consisting of 
adducts, artifacts, isomers, and metabolites. the applied untargeted metabolomics strategy was able 
to find almost all of the metabolites that were previously described for 1-phenyl-2-(1-pyrrolidinyl)-1-
butanone in literature as well as three additional metabolites. Concerning 1-phenyl-2-(1-pyrrolidinyl)-
1-heptanone biotransformation in pHLM, merely four metabolites described in primary human 
hepatocytes and human urine were not found. this study revealed that untargeted metabolomics 
workflows are well suited to support biotransformation studies at least of the investigated compounds 
in pHLM.
Knowledge about the metabolism of abused drugs is often essential for a reliable confirmation of an intake by 
patients in clinical and forensic toxicology1. This can especially be the case if metabolites are the only targets for 
their detection in urine2. According to the World Drug Report 20183,4, 803 new psychoactive substances (NPS) 
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were reported between 2009 and 2017. These substances are often legally available while the health risk they entail 
remains unknown. This implies that continuous metabolism studies are necessary. Due to the lack of authentic 
human urine, such studies are often performed in advance using different in vitro and in vivo models such as 
pooled human liver microsomes (pHLM), pooled human liver S9 fraction (pS9), or rat urine2,5. pHLM is the most 
frequently used in vitro model, since it is easily accessible and the majority of drugs undergoes merely cytochrome 
P450 (CYP) mediated oxidation as well as uridine 5′-diphospho-glucuronosyltransferase mediated glucuronida-
tion6. Both enzyme classes are located at the smooth endoplasmic reticulum that is part of the microsomal frac-
tion5. The identification of metabolites is then conducted by comparing the fragmentation pattern of the parent 
compound with that of putative metabolites after mass spectrometry (MS) coupled to liquid (LC)- or gas chroma-
tography (GC)2,7–9. Metabolism leads to changes in the chemical structure that can be identified by specific shifts 
in the fragmentation pattern1. This approach of discovering and identifying metabolites relies on the individual 
skills of the scientist that classifies a compound as a metabolite, based on the experience and knowledge of drug 
metabolism and interpretation of mass spectra.
The dependency on the experience of individuals is a drawback that might at least be avoided concerning the 
relevance of an analyte by application of metabolomics techniques, amongst others. Metabolomics in general 
means the analysis of the whole metabolome (e.g. in urine) and thus aims to detected as many metabolites as 
possible10. In case of human urine this includes metabolites that arise from food, physiological processes, or 
the gut microbiome10 and very likely also may include NPS metabolites. Metabolomics can be divided into two 
groups. The first one, targeted metabolomics, aims to analyze certain metabolites found relevant and often also 
quantify their changes. This implies that the metabolites of interest are already known and their relevance has 
been confirmed. For the investigation of the metabolism of abused drugs (e.g. NPS), such an approach is usually 
not appropriate since the metabolic pathways still need to be revealed. The identification of relevant metabolites 
is carried out by untargeted metabolomics (UM). This kind of study provides an impartial approach on every 
peak that was recorded during the mass spectral analysis. It uses statistical evaluation of the peak abundances 
to highlight significant changes between two or more investigated groups11. After the detection by an algorithm, 
chromatographic peaks are usually called features that are statistically assessed.
This study aimed to evaluate untargeted metabolomics strategies for the identification of metabolites of 
NPS. The evaluation was conducted by investigating the metabolism of the two synthetic cathinones alpha-PBP 
(1-phenyl-2-(1-pyrrolidinyl)-1-butanone) and alpha-PEP (1-phenyl-2-(1-pyrrolidinyl)-1-heptanone, see Fig. 1) 
in pHLM incubations and compare the findings to previous metabolism studies12–14. Those previous studies 
revealed that both substances form several CYP-mediated metabolites. Furthermore, glucuronides were found 
in human urine.
experimental
Chemicals and reagents. alpha-PBP and alpha-PEP were provided by the Bavarian State Criminal Police 
Office (Munich, Germany). NADP-Na2, acetonitrile (LC-MS grade), and methanol (LC-MS grade) were obtained 
from VWR (Darmstadt, Germany), MgCl2, K2HPO4, K3PO4, superoxide dismutase, isocitrate dehydrogenase, 
isocitrate, ammonium formate, ammonium acetate, and formic acid from Sigma (Taufkirchen, Germany). Water 
was purified with a Millipore filtration unit (18.2 Ω × cm water resistance). pHLM (pool of 25 donors, 20 mg 
microsomal protein/mL) were obtained from Corning (Amsterdam, The Netherlands). After delivery, the pHLM 
were thawed at 37 °C, aliquoted, snap-frozen in liquid nitrogen, and stored at −80 °C until use.
Microsomal incubations. Incubations using pHLM were performed according to Welter et al.15 alpha-PBP 
and alpha-PEP were freshly dissolved in 100 mM phosphate buffer and subsequently diluted to obtain the 
required concentrations in prior to the experiment. For UM, incubations were conducted at 37 °C using 0 (group 
Blank), 12.5 (group Low), or 25 µM (group High) substrate and 50 mg protein/mL pHLM. The final incuba-
tion volume was 50 µL and consisted of 90 mM phosphate buffer, 5 mM isocitrate, 5 mM Mg2+, 1.2 mM NADP+, 
200 U/mL superoxide dismutase, and 0.5 U/mL isocitrate dehydrogenase. The mixture was preincubated for 
10 min, reaction was started by the addition of substrate. After 60 min the reaction was stopped by adding 50 µL 
of ice-cold acetonitrile and the mixture was subsequently centrifuged for 2 min at 14,000 × g. These incubations 
were performed in five replicates for every group. 10 µL of each incubation were transferred into one MS vial. This 
pooled sample mixture (group QC) was used for optimization of peak picking and batch correction as described 
below. 70 µL of the remaining supernatant were transferred into separate MS vials.
For the identification of significant features, incubations were repeated in duplicates using 0 (substrate blank), 
12.5, and, 25 µM of substrate. Additionally, incubations were performed not containing pHLM but corresponding 
amounts of phosphate buffer and 25 µM substrate (enzyme blank). Each of these incubations was conducted as 
described above.
Figure 1. Chemical structures of the investigated compounds.
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LC-HRMS/MS apparatus. The analysis was performed using a Thermo Fisher Scientific (TF, Dreieich, 
Germany) Dionex UltiMate 3000 RS pump consisting of a degasser, a quaternary pump, and an UltiMate 
Autosampler, coupled to a TF Q-Exactive Plus system equipped with a heated electrospray ionization HESI-II 
source. Mass calibration was done prior to analysis according to the manufacturer’s recommendations using 
external mass calibration. Additionally before each experiment the apparatus’ spray shield and capillary was 
cleaned. The performance of the column and the mass spectrometer was tested using a test mixture as described 
by Maurer et al.1,16 in prior to every experiment. The conditions were set according to published procedures17,18. 
Gradient reversed phase elution was performed on a TF Accucore PhenylHexyl column (100 mm × 2.1 mm, 
2.6 µm) or a normal phase Macherey-Nagel (Düren, Germany) HILIC Nucleodur column (125 × 3 mm, 3 μm). 
The mobile phases for gradient elution using the PhenylHexyl column consisted of 2 mM aqueous ammonium 
formate containing acetonitrile (1%, v/v) and formic acid (0.1%, v/v, pH 3, eluent A), as well as 2 mM ammonium 
formate solution with acetonitrile:methanol (1:1, v/v) containing water (1%, v/v) and formic acid (0.1%, v/v, elu-
ent B). The flow rate was set from 1–10 min to 500 µL/min and from 10–13.5 min to 800 µL/min using the follow-
ing gradient: 0–1.0 min 99% A, 1–10 min to 1% A, 10–11.5 min hold 1% A, 11.5–13.5 min hold 99% A. The 
gradient elution using the HILIC column was performed using aqueous ammonium acetate (200 mM, eluent C) 
and acetonitrile containing formic acid (0.1%, v/v, eluent D). The flow rate was set to 500 µL/min using the follow-
ing gradient: 0–1 min 2% C, 1–5 min 20% C, 5–8.5 min 60% C, 8.5–10 min hold 60% C. 10–12 min hold 2% C. For 
preparation and cleaning of the injection system isopropanol:water (90:10, v/v) was used. The following settings 
were used: wash volume, 100 µL; wash speed, 4000 nL/s; loop wash factor, 2. Every analysis was performed at 
40 °C column temperature, maintained by a Dionex UltiMate 3000 RS analytical column heater. The injection 
volume for every analysis was 1 µL. The HESI-II source conditions for every experiment were as follows: ioniza-
tion mode, positive or negative; sheath gas, 60 AU; auxiliary gas, 10 AU; sweep gas, 3 AU; spray voltage, 3.50 kV in 
positive mode and −4.0 kV in negative mode; heater temperature, 320 °C; ion transfer capillary temperature, 
320 °C; and S-lens RF level, 50.0. Mass spectrometry for UM was performed according to a previously optimized 
workflow using full scan (FS) only19. The settings for FS data acquisition were as follows: resolution, 140,000 
fwhm; microscans, 1; automatic gain control (AGC) target, 5 × 105; maximum injection time, 200 ms; scan range, 
m/z 50–750; polarity, negative or positive; spectrum data type, centroid. Significant features were identified using 
parallel reaction monitoring (PRM). Settings for PRM data acquisition were as follows: resolution, 70,000 fwhm; 
microscans, 1; AGC target, 5 × 105; maximum injection time, 200 ms; isolation window, 0.4 m/z; normalized col-
lision energy (NCE), 35 eV; spectrum data type, centroid. The inclusion list contained the monoisotopic masses 
of all significant features and a time window of their retention time ±30 s. TF Xcalibur software version 3.0.63 was 
used for data handling. The analysis was performed using a randomized sequence order with five injections of 
pure methanol (PhenylHexyl column) or eluent D (HILIC column) samples at the beginning of the sequence for 
apparatus equilibration, followed by five injections of the pooled QC sample. Additionally, one QC injection was 
performed every five samples to monitor batch effects as described by Wehrens et al.20.
Data processing. Thermo Fisher LC-HRMS/MS RAW files were converted into mzXML files using Proteo 
Wizard21. Peak picking was performed using XCMS in an R environment22,23, annotation of isotopes, adducts, and 
artifacts was performed using the R package CAMERA24. Optimization of XCMS parameters was in accordance 
to a previously optimized strategy19. Peak picking and alignment parameters are summarized in Table S1. After 
peak picking, fold changes of features between the groups Blank and Low, Blank and High, as well as Low and 
High were calculated. A corresponding p-value was calculated using Welsh’s two sample t-test. The data set was 
filtered keeping merely those features with a fold change <−1.5 or >1.5 and a corresponding p-value of <0.001 
in one of the group comparisons. Additionally, every feature with a retention time lower than 60 s or higher than 
600 s was removed, since they were acquired during column acquisition or washing phase of the chromatography. 
According to Wehrens et al.20 feature abundances with a value of zero were replaced by the lowest measured abun-
dance as a surrogate LOD and subsequently log10 transformed. A batch correction was performed for those fea-
tures that were detected in every QC sample. The corresponding feature abundance was corrected using a linear 
model to extrapolate its abundance drift between QC samples20. Patterns in the data set were subsequently inves-
tigated using principal component analysis (PCA), t-distributed stochastic neighborhood embedding (t-SNE)25,26 
and hierarchical clustering. Names of the features were adopted from XCMS using “M” followed by the rounded 
mass and “T” followed by the retention time in seconds (e.g. “M218T216” as given in Table 1 for protonated 
alpha-PBP at m/z 218.1540 and a retention time of 216 s using a PhenylHexyl column).
Results and Discussion
Untargeted metabolomics. Volcano plots of detected features are shown in Figures S1–S8, Scores and 
Loadings of the PCA in Figures S9 and S10. Results of t-SNE and heat maps of hierarchical clustering are pre-
sented in Figs 2 and 3. The first of five QC samples that were analyzed before samples from the different incu-
bation groups during the analysis of alpha-PEP using HILIC and positive ionization mode had to be excluded 
due to a high sensitivity loss of the MS during the analysis. Almost none of the analyses using negative mode 
revealed significant features. An exception was the analysis of alpha-PEP in HILIC/negative mode (Figure S8). 
PCA revealed that more than 95% of the variance was stored in the first principal component leading to the 
conclusion that the data is characterized by a high amount of collinearity (Fig. S9A–D). This is not a surprise 
regarding the high amount of parent compound in relation to other substances within the incubation mixture. 
Samples of the group Blank also persistently displayed a high variability within their group throughout most of 
the analyses indicating a high variance in the measured peak abundances. Such high variance is also explainable 
by the study design since the variance in the data set primarily originated from the addition of parent compound 
and the subsequent formation of metabolites. If a peak was detected and integrated by XCMS it also reintegrated 
the same region in other samples where they were originally not detected. Regarding that samples of the group 
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Blank did not contain any parent compound or metabolite, XCMS merely integrated noise that resulted in peak 
areas with a high variance between different samples which is visible in these score plots. An exception was the 
analysis of alpha-PEP using HILIC in negative mode (Fig. S9E). Since neither the parent compounds nor their 
metabolites did contain any structural elements such as halogen atoms or carboxylic acids that can be ionized in 
negative mode under the given conditions, the above-mentioned restrictions did not apply here. The correspond-
ing loadings (Figure S10 E) showed that the three features that were found significant in this analysis contributed 
evenly to the group separation.
These findings implied that even though PCA is a widely used technique for untargeted metabolomics, it was 
not suitable for those experiments where the substrate and its metabolites were detectable. Patterns in the data 
were therefore investigated using t-SNE, a dimension reduction algorithm that visualized similarities in the data 
set26. The t-SNE plots resulted in a more appropriate clustering of the groups (Fig. 1) with evenly distributed dis-
tances. QC samples appear very close or within the cluster of samples from the group Low. This is not surprising 
since the pooled sample QC consists of a mixture of every incubation sample and thus contains parent compound 
and its metabolites in an approximate concentration of the samples from group Low. Differences between both 
group Low and QC might appear due to inaccuracy when preparing the pooled sample QC or a nonlinear metab-
olite formation in the given concentrations during incubation.
Clustering patterns of t-SNE corresponded to those obtained by hierarchical clustering (Fig. 2). Every analysis 
in positive mode showed a clear discrimination between samples from the group Blank and the remaining ones. 
The only exception again was the analysis of alpha-PEP using HILIC (Fig. 2E), were QC samples appeared in the 
same class as samples from the group Blank. The corresponding z-scores indicated a correlation of the features’ 
peak abundances with the clustering. It is noteworthy that in the analysis of alpha-PBP in positive mode using the 
PhenylHexyl column (Fig. 2A), the feature M217T214 showed a positive z-score in the groups Blank and High, 
but a negative z-score in the groups Low and QC what implied a corresponding decrease of the peak abundances. 
However, this feature was annotated by CAMERA as a 13C isotope (see Table 1) whose peak abundance should 
increase with increasing concentrations of the parent compound. Inspection of the chromatograms as detected 
by XCMS revealed a coeluting peak and the beginning of a baseline drift27 that artificially increased the peak 
abundance of those peaks from the group Blank.
Identification of significant features. The results of the identification of significant features is summa-
rized in Tables 1–4. Isotopes that were annotated by CAMERA were not further analyzed. Every other feature was 
analyzed as described above using a PRM method and the resulting mass spectra are shown in Figures S9-S13. 
The Metabolomics Standards Initiative proposed minimum information that need to be supplied when reporting 
metabolomics experiments28. These include a classification of the identification level by four categories. The first 
category is the most valid identification level using two orthogonal data sets. The last category means an uni-
dentified metabolite. Due to the lack of reference compounds, the proposed structural formulas were deduced 
by comparing the spectra of the metabolites with those of the parent compounds or reference spectra using the 
METLIN and Human Metabolome Database (HMDB)28,29. This approach is referred to as category two in the 
above mentioned publication, meaning a putatively annotated compound. It applies to all of the identified com-
pounds except for M417T103 and M434T104 in Table 4 which are yet unknown and therefore category four. The 
fragmentation of both substances was already described in previous publications14 and will not further be dis-
cussed here. Concerning the incubations using alpha-PBP, significant features consisted of six isotopes, three arti-
facts, five metabolites, one adduct, and one impurity. alpha-PBP itself formed one in-source artifact (M216T214 
in Table 1 and M216T347 in Table 2). It was the result of an oxidation of the pyrrolidine ring. The formation of the 
artifact within the ion source was assumed since its retention time was similar to that of the parent compound. 
The oxidation of the pyrrolidine ring was additionally found at a different retention time using HILIC (M216T114 
in Table 2) implying that this compound was not formed within the ion source. Since it was also contained in the 
enzyme blank but not in the substrate blank sample it is very likely that this compound is an impurity of the pow-
der that was seized by the Bavarian State Criminal Police Office. In addition to the in-source artifact there were 






pos M216T214 216.1383 214 alpha-PBP artifact (dehydro-)
pos M217T214 217.1415 214 alpha-PBP artifact (dehydro-) 13C isotope
pos M218T216 218.1540 216 alpha-PBP
pos M219T216 219.1572 216 alpha-PBP 13C-isotope
pos M220T226 220.1695 226 alpha-PBP-M (dihydro-)
pos M221T226 221.1728 226 alpha-PBP-M (dihydro-) 13C-isotope
pos M232T343 232.1331 343 alpha-PBP-M (oxo-)
pos M236T214 236.1643 214 alpha-PBP-M (dihydro-HO-)
pos M237T214 237.1676 214 alpha-PBP-M (dihydro-HO-) 13C-isotope
pos M250T215 250.1435 215 alpha-PBP-M (di-HO-)
Table 1. Significant features of alpha-PBP after untargeted analysis using a reversed phase (PhenylHexyl) 
column. Features are ordered by m/z and retention time. Isotopes were annotated by the R package CAMERA 
and not further identified. Metabolites are indicated by bold font. pos = positive.
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Figure 2. Results of t-SNE. A = alpha-PBP, PhenylHexyl column, positive mode; B = alpha-PBP, HILIC 
column, positive mode; C = alpha-PEP, PhenylHexyl column, positive mode; D = alpha-PEP, HILIC column, 
positive mode; E = alpha-PEP, HILIC column, negative mode.
Figure 3. Heat maps of hierarchical clustering. A = alpha-PBP, PhenylHexyl column, positive mode; B = 
alpha-PBP, HILIC column, positive mode; C = alpha-PEP, PhenylHexyl column, positive mode; D = alpha-
PEP, HILIC column, positive mode; E = alpha-PEP, HILIC column, negative mode.
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The first one contains an imide group instead of a cathinone oxo group and an oxidized pyrrolidine ring. The 
introduction of an imide could theoretically be conducted by the inversion of a deamination reaction but such a 
metabolism step has never been reported before and was therefore classified as an artifact of the dehydro impu-
rity. The second artifact contains a cyano group which cannot be introduced by human enzymes. The formation 
of this artifact might have been occurred within the ion source while using acetonitrile as an eluent or after ter-
minating the incubation with acetonitrile. One dihydro metabolite (M220T355 in Table 2) was found, that was 
not sufficiently separated from the alpha-PBP isotope containing two 13C atoms during the analysis using HILIC. 
The result of the PRM analysis was therefore a mixed MS2 spectrum containing fragments from both parent ions 
(see Fig. S10). The separation of both compounds was possible after using an alternative chromatography with 
a flatter increase of eluent D. The employed gradient as well as the obtained chromatogram and MS2 spectra are 
displayed in Figure S14.
The significant features identified in the incubations using alpha-PEP consisted of seven isotopes, four arti-
facts, nine metabolites, two impurities, one endogenous compound, and two yet unidentified compounds. For 
the parent compound of alpha-PEP two features with different abundances were found showing the same frag-
mentation but different abundances of the corresponding fragments (M260T312 and M260T296 in Table 3, as 
well as M260T243 and M260T276 in Table 4). A considerable difference between the MS2 spectra is the huge 
intensity of the fragment at m/z 242.1901 in Fig. S11 and m/z 242.1903 in Fig. S12. This fragment occurs after 
the initial elimination of the cathinone oxo group and leads to the conclusion that these conformers arise from a 






pos M215T328 215.1542 328 alpha-PBP impurity (dehydro-) artifact (imido-)
pos M216T114 216.1383 114 alpha-PBP impurity (dehydro-)
pos M216T347 216.1383 347 alpha-PBP artifact (dehydro-)
pos M218T351 218.1541 351 alpha-PBP
pos M219T350 219.1572 350 alpha-PBP 13C-isotope
pos M220T355 220.1694 355 alpha-PBP-M (dihydro-)
pos M221T355 221.1726 355 alpha-PBP-M (dihydro-) 13C-isotope
pos M234T114 234.1488 114 alpha-PBP-M (dihydro-oxo-)
pos M236T367 236.1643 367 alpha-PBP-M (dihydro-HO-)
pos M237T367 237.1677 367 alpha-PBP-M (dihydro-HO-) 13C-isotope
pos M243T80 243.1492 80 alpha-PBP impurity (dehydro-) artifact (cyano-)
pos M250T412 250.1436 412 alpha-PBP-M (di-HO-)
pos M471T350 471.2771 350 alpha-PBP adduct [2 M + 2 H + Cl]+
pos M472T350 472.2805 350 alpha-PBP adduct [2 M+2 H+Cl]+ 13C-isotope
pos M473T350 473.2742 350 alpha-PBP adduct [2 M+2 H+Cl]+ 13C2-isotope
Table 2. Significant features of alpha-PBP after untargeted analysis using a normal phase (HILIC) column. 
Features are ordered by m/z and retention time. Isotopes were annotated by the R package CAMERA and not 






pos M206T296 206.1538 296 alpha-PEP-M (N,N-dealkyl-)
pos M258T312 258.1852 312 alpha-PEP artifact (dehydro-)
pos M260T296 260.2008 296 alpha-PEP conformer 2
pos M260T312 260.2009 312 alpha-PEP conformer 1
pos M261T312 261.2042 312 alpha-PEP 13C-isotope
pos M262T312 262.2073 312 alpha-PEP 13C2-isotope
pos M262T325 262.2165 325 alpha-PEP-M (dihydro-)
pos M263T324 263.2197 324 alpha-PEP-M (dihydro-) 13C-isotope
pos M274T425 274.1799 425 alpha-PEP-M (oxo-)
pos M276T229 276.1958 229 alpha-PEP-M (HO-) isomer 2
pos M277T229 277.1990 229 alpha-PEP-M (HO-) isomer 2 13C-isotope
pos M278T307 278.2113 307 alpha-PEP-M (dihydro-HO-)
pos M292T310 292.1904 310 alpha-PEP-M (di-HO-)
Table 3. Significant features of alpha-PEP after untargeted analysis using a reversed phase (PhenylHexyl) 
column. Features are ordered by m/z and retention time. Isotopes were annotated by the R package CAMERA 
and not further identified. Metabolites are indicated by bold font. pos = positive.
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dihydro metabolites of alpha-PEP (M262T271 and M262T282 in Table 4). Since the reduction of the cathinone 
oxo group introduces an additional stereo center into the molecule, these two features are most likely different 
diastereomers of the same compound. Due to an insufficient separation, the analysis using a PhenylHexyl column 
merely revealed one feature identified as a dihydro metabolite (M262T325 in Table 3). One of the artifacts that 
were found in the analysis of alpha-PEP was also an in-source artifact of the parent compound and followed the 
same formation principle as that of alpha-PBP (M258T312 in Table 3, M258T249 in Table 4). An impurity with an 
oxidized pyrrolidine ring was also found (M246T254 in Table 4), forming the same artifacts as already described 
for the analysis of alpha-PBP (M257T216 and M285T74 in Table 4). Another feature was identified as compound 
with a shorter alkyl chain (M246T254in Table 4). Alkyl chain shortening may be a result of human fatty acid like 
metabolism. The the β-oxidation usually results in carboxylic acids that are further broken down by subsequent 
oxidation steps. However, the identified compound did not contain such structural elements leading to the con-
clusion that it might also be an impurity.
The analysis of alpha-PEP using HILIC and negative ionization mode revealed three significant features. The 
fragmentation of these features could not be explained by using the parent compound fragmentation leading to 
the assumption that these features might be endogenous compounds. For further identification, the METLIN 
and the HMDB were searched using the MS/MS search method of both databases and the respective MS2 spectra. 
The precursor m/z deviation was set to a maximum of 5 ppm, the m/z deviation of the corresponding fragments 
was set to 0.01 Da for METLIN and 10 ppm for HMDB. One feature (M327T82 in Table 4) was identified as 
Docosahexaenoic acid (Metlin ID: 3457, HMDB0002183) with a METLIN score of 58 and a HMDB fit of 85%. 
Both databases matched the compound to experimental MS/MS data. Docosahexaenoic acid is an important 
structural component of the human brain, cerebral cortex, and the discs of the rod photoreceptor cells. It can be 
provided via animal fats or converted from alpha-linolenic acid and linoleic acid in the human liver30. Since doco-
sahexaenoic acid was the only lipid that was found in this study the cause of its enrichment in incubations with 
alpha-PEP remains speculative. The remaining features (M417T103 and M434T104 in Table 4) are yet unknown 
since their spectra did not lead to any match in the above-mentioned databases. Their MS2 spectra needed to be 
recorded using an isolation window of m/z 1 to obtain sufficient scan points. Since they could not be identified, 
their spectra were additionally recorded using an isolation window of m/z 1 to obtain sufficient scan points and 
collision energies of 10, 20, and 40 eV. Mass spectra were included in Figure S13 without the annotation of a puta-






pos M246T254 246.1849 254 alpha-PHP impurity
pos M257T216 257.2008 216 alpha-PEP impurity (dehydro-) artifact (imido-)
pos M258T198 258.1849 198 alpha-PEP impurity (dehydro-)
pos M258T216 258.2042 216 alpha-PEP impurity (dehydro) artifact (imido-) C13-isotope
pos M258T249 258.1849 249 alpha-PEP artifact (dehydro-)
pos M260T243 260.2007 243 alpha-PEP conformer 1
pos M260T276 260.2005 276 alpha-PEP conformer 2
pos M261T243 261.2040 243 alpha-PEP 13C-isotope
pos M262T243 262.2071 243 alpha-PEP 13C2 isotope
pos M262T271 262.2162 271 alpha-PEP-M (dihydro-) diastereomer 1
pos M262T282 262.2162 282 alpha-PEP-M (dihydro-) diastereomer 2
pos M263T270 263.2195 270 alpha-PEP-M (dihydro-) diastereomer 1 13C-isotope
pos M263T282 263.2195 282 alpha-PEP-M (dihydro-) diastereomer 2 13C-isotope
pos M272T87 272.1641 87 alpha-PEP-M (oxo-HO-) isomer 2 artifact
pos M276T90 276.1954 90 alpha-PEP-M (dihydro-oxo-)
pos M276T269 276.1954 269 alpha-PEP-M (HO-) isomer 1
pos M276T316 276.1954 316 alpha-PEP-M (HO-) isomer 2
pos M277T269 277.1987 269 alpha-PEP-M (HO-) isomer 1 13C-isotope
pos M277T316 277.1987 316 alpha-PEP-M (HO-) isomer 2 13C-isotope
pos M278T291 278.2110 291 alpha-PEP-M (dihydro-HO-)
pos M285T74 285.1957 74 alpha-PEP impurity (dehydro-) artifact (cyano-)
pos M290T93 290.1746 93 alpha-PEP-M (oxo-HO-) isomer 1
pos M292T321 292.1901 321 alpha-PEP-M (di-HO-)
neg M327T82 327.2323 82 Docosahexaenoic acid
neg M417T103 417.1910 103 Unknown
neg M434T104 434.1811 104 Unknown
Table 4. Significant features of alpha-PEP after untargeted analysis using a normal phase (HILIC) column. 
Features are ordered by m/z and retention time. Isotopes were annotated by the R package CAMERA and not 
further identified. Metabolites are indicated by bold font. pos = positive, neg = negative.
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Metabolism of alpha-PBP and alpha-PEP in pHLM. The metabolic pathways of alpha-PBP and 
alpha-PEP in pHLM as elucidated by this study are represented by Figs 4 and 5. alpha-PBP was reduced at the 
cathinone oxo group resulting in a dihydro metabolite. The pyrrolidine ring underwent metabolism resulting 
in an oxo and a dihydroxy metabolite as well as a ring opened hydroxy metabolite. The oxo group was sug-
gested to be in ortho position due to the retention time of the metabolite. The oxo metabolite was eluting later 
than the parent compound using a PhenylHexyl column and earlier using HILIC. This allowed the conclusion 
that this compound should be more lipophilic. Higher lipophilic properties of oxo metabolites can be explained 
by the existence of a lactam. This finding is in accordance to previous publications investigating the metabo-
lism of alpha-cathinones and one study describing the biotransformation of nitrogen containing xenobiotics to 
lactams13,31–34. The opening of the pyrrolidine ring is very likely the result of a hydroxylation in ortho position of 
the pyrrolidine ring followed by a retro-hemiaminal reaction. The resulting aldehyde was finally reduced forming 
the hydroxy group. Additionally, a combination of the dihydro and the oxo metabolite was found. The metabo-
lism of alpha-PBP in pHLM and pS9 has already been investigated by Manier et al., as well as in human urine by 
Matsuta et al.12,14. Most metabolites found in this study were already described in these publications. Nevertheless, 
the UM approach was able to additionally identify a di-hydroxy metabolite, a ring opened dihydro hydroxy 
metabolite, as well as a dihydro oxo metabolite. The dihydro metabolite was not found in previous pHLM and pS9 
investigations but in human urine. This might be due to the case, that the dihydro metabolite showed a similar 
retention time as the parent compound when using a PhenylHexyl column and is thus hard to distinguish from 
the parent compound isotope containing two 13C atoms. The above described mass spectrometer settings with a 
resolution of 140,000 fwhm however allowed to distinguishing both peaks. Matsuta et al. were able to separate the 
dihydro metabolite from the parent compound since they used gas chromatography12. The hydroxy metabolite 
Figure 4. Metabolic pathways of alpha-PBP in pHLM. Undefined position of hydroxylation indicated by 
unspecific bonds. Two arrows indicate a pathway that contains multiple metabolism steps. Every metabolite is 
annotated with its feature identifier from untargeted metabolomics analyses. PH = PhenylHexyl column, H = 
HILIC column.
9Scientific RepoRts |          (2019) 9:2741  | https://doi.org/10.1038/s41598-019-39235-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
described by Manier et al. in previous studies was not found by the metabolomics approach used in this study. 
Considering that Matsuta et al. did not find a hydroxy metabolite in human urine12 leads to the assumption that 
this metabolite is not a primary target and is formed only in very small amounts in vitro, which might explain the 
non-detection via automated peak picking.
alpha-PEP also underwent reduction of the cathinone oxo group resulting in a dihydro metabolite. The pyrro-
lidine ring was metabolized resulting in an oxo, two hydroxy, and one dihydroxy metabolite. The position of the 
oxo group was again determined in ortho to the pyrrolidine nitrogen due to the above-mentioned characteristics. 
The position of the hydroxy groups in the dihydroxy metabolite was determined as vicinal to the nitrogen in the 
pyrrolidine ring since it is likely that this metabolite leads to the N,N-dealkyl metabolite that was also detected. In 
addition to these pathways, alpha-PEP was hydroxylated at the alkyl chain leading to a mono hydroxy metabolite 
as well as a hydroxylated oxo metabolite. The formation of a ring opened hydroxy metabolite was found as well 
and likely resulted from the metabolism steps already described for alpha-PBP.
Previous investigations on the metabolism of alpha-PEP were performed by Manier et al. using pHLM and 
pS9 as well as Swortwood et al. using primary human hepatocytes (PHH) and human urine13. The metabolomic 
approach after pHLM incubation used in this study was able to reveal all of the metabolites previously found after 
incubations using pHLM and additionally most of those found in pS9, PHH, and human urine. Metabolites that 
were not found by the metabolomic approach were primarily those that resulted from dehydrogenation, as well as 
the carboxylic acid that likely resulted from hydrolysis of the lactam metabolite. This might have been the result 
of limitations of the chosen pHLM model in comparison to PHH and human urine.
Conclusions
In vitro metabolism studies using pHLM in combination with untargeted metabolomics resulted in the detec-
tion of 24 significant features for alpha-PBP and 39 significant features for alpha-PEP. Most of these features 
were artifacts, isotopes, conformers, diastereomers, or adducts. Nevertheless, metabolites were identified that 
corresponded well with those from previous investigations using pHLM, pS9, PHH, and human urine12–14. 
For alpha-PBP three metabolites were found that were not described in any of the previous publications. 
Investigations of alpha-PEP in pHLM revealed known metabolites but missed those additionally found in 
PHH and human urine, which is most likely due to enzymatic differences between pHLM and the other mod-
els. Besides metabolites of the parent compounds, this study was also able to reveal changes within the incuba-
tion mixture after exposure to the drugs. After the incubation of alpha-PEP, docosahexaenoic acid was found 
enriched, while two yet unidentified compounds showed a significant decrease in their peak abundances. This 
Figure 5. Metabolic pathways of alpha-PEP in pHLM. Undefined position of hydroxylation indicated by 
unspecific bonds. Two arrows indicate a pathway that contains multiple metabolism steps. Every metabolite is 
annotated with its feature identifier from untargeted metabolomics analyses. PH = PhenylHexyl column, H = 
HILIC column.
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study demonstrated that the developed untargeted metabolomics approach allows detection of in vitro metabo-
lites of NPS after pHLM incubation besides the detection of further compounds by using an investigator inde-
pendent approach.
Data Availability
Datasets generated during and/or analyzed during the current study are not publicly available but are available 
from the corresponding author on reasonable request.
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